Changes in the clearance of total and unbound etoposide in patients with liver dysfunction

Journal of Clinical Oncology

Volumn 8, Issue 11, 1990, Pages 1874-1879

  Stewart, Clinton F ^a   Arbuck, Susan G ^b   Fleming, Ronald A ^b   Evans, William E ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; CREATININE; ETOPOSIDE; FEMALE; HUMAN; LIVER; LIVER FUNCTION TESTS; MALE; NEOPLASMS; PROTEIN BINDING; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025169552     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1990.8.11.1874     Document Type: Article

References (20)

1. Fleming RA, Miller AA, Stewart CF: Etoposide - An update. Clin Pharm 8:274-293, 1989
2. Arbuck SG, Douglass HO, Crom WR, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690-1695, 1986
3. 14-C etoposide. Proc Am Assoc Cancer Res 30:536, 1989 (abstr)
4. Creaven PJ, Alien LM: EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:221-226, 1975
5. D'Incalci M, Rossi C, Zucchetti M, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566-2571, 1986
6. Hande KR, Combs GL, Cotham R, et al: Biliary clearance and hepatic metabolism of etoposide (VP-16). Proc Am Soc Clin Oncol 4:34, 1985 (abstr)
7. Stewart CF, Arbuck SG, Pieper JA, et al: Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 45:49-55, 1989
8. Riley CA, Crom WR, Evans WE: Loop column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma. Ther Drug Monit 7:455-460, 1985
9. Sinkule JA, Evans WE: High performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 73:164-168, 1984
10. Huang J: Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 72:1368-1369, 1983
11. Bjornsson TD, Brown JE, Tschanz C: Importance of radiochemical purity of radiolabeled drugs used for determining plasma protein binding of drugs. J Pharm Sci 70:1372-1373, 1981
12. Yeh KC, Kwan KC: A comparison of numerical integrating algorithms by trapezoidal, LaGrange, and spline approximations. J Pharmacokin Biopharm 6:79-98, 1978
13. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
14. Ryan TA, Joiner BL, Ryan BF: MINITAB Student Handbook. North Scituate, MA, Duxburg Press, 1985
15. Svensson CK, Woodruff MN, Lalka D: Influence of protein binding and use of unbound (free) drug concentrations, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, WA, Applied Therapeutics, 1986 pp 187-220
16. Bennett CL, Sinkule JA, Schilsky RL, et al: Phase I clinical and pharmacological study of seventy-two hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952-1956, 1987
17. Ratain MJ, Schilsky RL, Choi KE, et al: Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45:226-330, 1989
18. Miller AA, Stewart CF, Tolley EA: Clinical pharmacodynamics of continuous infusion etoposide. Cancer Chemo Pharmacol 1989
19. Stewart CF, Arbuck SG, Fleming RA, et al: Leukopenia and etoposide systemic exposure: Clinical relevance of nonprotein bound etoposide. Proc Am Soc Clin Oncol 8:71, 1989 (abstr)
20. Perry MC: Hepatotoxicity of chemotherapeutic agents. Semin Oncol 9:65-74, 1982